JP2022552153A5 - - Google Patents
Info
- Publication number
- JP2022552153A5 JP2022552153A5 JP2022520449A JP2022520449A JP2022552153A5 JP 2022552153 A5 JP2022552153 A5 JP 2022552153A5 JP 2022520449 A JP2022520449 A JP 2022520449A JP 2022520449 A JP2022520449 A JP 2022520449A JP 2022552153 A5 JP2022552153 A5 JP 2022552153A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- cancer
- binding fragment
- antibody
- kir3dl3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025121256A JP2025142220A (ja) | 2019-10-04 | 2025-07-18 | 抗ｋｉｒ３ｄｌ３抗体およびそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962910594P | 2019-10-04 | 2019-10-04 | |
| US62/910,594 | 2019-10-04 | ||
| PCT/US2020/054063 WO2021067800A1 (en) | 2019-10-04 | 2020-10-02 | Anti-kir3dl3 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025121256A Division JP2025142220A (ja) | 2019-10-04 | 2025-07-18 | 抗ｋｉｒ３ｄｌ３抗体およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022552153A JP2022552153A (ja) | 2022-12-15 |
| JP2022552153A5 true JP2022552153A5 (enExample) | 2023-10-10 |
| JP7716393B2 JP7716393B2 (ja) | 2025-07-31 |
Family
ID=75336592
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520449A Active JP7716393B2 (ja) | 2019-10-04 | 2020-10-02 | 抗ｋｉｒ３ｄｌ３抗体およびそれらの使用 |
| JP2025121256A Pending JP2025142220A (ja) | 2019-10-04 | 2025-07-18 | 抗ｋｉｒ３ｄｌ３抗体およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025121256A Pending JP2025142220A (ja) | 2019-10-04 | 2025-07-18 | 抗ｋｉｒ３ｄｌ３抗体およびそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250388702A1 (enExample) |
| EP (1) | EP4041403A4 (enExample) |
| JP (2) | JP7716393B2 (enExample) |
| KR (1) | KR20220110176A (enExample) |
| CN (1) | CN114729052B (enExample) |
| AU (1) | AU2020358867A1 (enExample) |
| CA (1) | CA3155681A1 (enExample) |
| IL (1) | IL291546A (enExample) |
| MX (1) | MX2022003833A (enExample) |
| WO (1) | WO2021067800A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022012725A2 (pt) * | 2019-12-24 | 2022-11-16 | Jjp Biologics Sp Z O O | Anticorpos hvem (tnfrsf14) anti-humanos e usos dos mesmos |
| IL314839A (en) * | 2022-02-22 | 2024-10-01 | Nextpoint Therapeutics Inc | KIR3DL3 inhibitors and immune cell activating agents |
| CN116083369B (zh) * | 2022-09-01 | 2025-05-09 | 华中科技大学同济医学院附属同济医院 | 双特异性抗体修饰囊泡、双特异性抗体、核酸、重组载体、基因工程细胞、方法和应用 |
| CN116286666B (zh) * | 2023-05-15 | 2023-08-04 | 成都云测医学生物技术有限公司 | 滋养层细胞及其制备方法、应用和扩增nk细胞的方法 |
| CN119841949B (zh) | 2023-10-17 | 2026-06-05 | 科辉智药(深圳)新药研究中心有限公司 | 一种抗人hhla2的纳米抗体及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2601417C (en) * | 2004-07-01 | 2018-10-30 | Novo Nordisk A/S | Human anti-kir antibodies |
| WO2012080891A1 (en) * | 2010-12-15 | 2012-06-21 | Rinat Neuroscience Corp. | Anti-notch-1 antibodies |
| CN102250910B (zh) * | 2011-05-31 | 2013-01-30 | 苏州大学 | 一种人可溶性b7-dc定量检测试剂盒 |
| CN111499755A (zh) * | 2012-08-03 | 2020-08-07 | 丹娜法伯癌症研究院 | 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法 |
| WO2015187359A1 (en) * | 2014-06-04 | 2015-12-10 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for targeting a pathway |
| WO2018073363A1 (en) * | 2016-10-21 | 2018-04-26 | Innate Pharma | Treatment with anti-kir3dl2 agents |
-
2020
- 2020-10-02 US US17/766,287 patent/US20250388702A1/en active Pending
- 2020-10-02 JP JP2022520449A patent/JP7716393B2/ja active Active
- 2020-10-02 MX MX2022003833A patent/MX2022003833A/es unknown
- 2020-10-02 KR KR1020227014642A patent/KR20220110176A/ko active Pending
- 2020-10-02 CN CN202080081278.XA patent/CN114729052B/zh active Active
- 2020-10-02 CA CA3155681A patent/CA3155681A1/en active Pending
- 2020-10-02 WO PCT/US2020/054063 patent/WO2021067800A1/en not_active Ceased
- 2020-10-02 AU AU2020358867A patent/AU2020358867A1/en active Pending
- 2020-10-02 EP EP20871762.9A patent/EP4041403A4/en active Pending
-
2022
- 2022-03-21 IL IL291546A patent/IL291546A/en unknown
-
2025
- 2025-07-18 JP JP2025121256A patent/JP2025142220A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021520208A5 (enExample) | ||
| JP6823094B2 (ja) | Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン | |
| RU2020136055A (ru) | Kir3dl3 в качестве рецептора hhla2, анти-hhla2-антител и его использование | |
| Scott et al. | Antibody therapy of cancer | |
| Liu et al. | 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma | |
| McDermott et al. | Preclinical efficacy of the antibody–drug conjugate CLDN6–23-ADC for the treatment of CLDN6-positive solid tumors | |
| Zekri et al. | An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer | |
| CN112969476B (zh) | 多特异性蛋白分子 | |
| EP3892639A1 (en) | Cd3 antibody and pharmaceutical use thereof | |
| Michelakos et al. | B7-H3 targeted antibody-based immunotherapy of malignant diseases | |
| JP2016500655A5 (enExample) | ||
| Mehta et al. | A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL | |
| CN103827144B (zh) | 新的抗cxcr4抗体及其用于检测和诊断癌症的用途 | |
| US12222356B2 (en) | Cytokine profiling analysis | |
| JP2020529839A5 (enExample) | ||
| JP2013527761A5 (enExample) | ||
| SA112330278B1 (ar) | مواد ضابطة جديدة وطرق للاستخدام | |
| Imakiire et al. | Generation, immunologic characterization and antitumor effects of human monoclonal antibodies for carcinoembryonic antigen | |
| JP2023527937A5 (enExample) | ||
| JP7713995B2 (ja) | ヒトｐｄ－ｌ１およびｐｄ－ｌ２に対する二重特異性抗体およびその使用方法 | |
| AU2017358359B2 (en) | Antibody binding specifically to CD66c and use thereof | |
| JP2021528047A5 (enExample) | ||
| JP2019512207A5 (enExample) | ||
| JP2020523029A5 (enExample) | ||
| WO2022152185A1 (zh) | 靶向cd5的全人源抗体 |